Background Bipolar depression accounts for most of the disease duration in type I and type
II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals …

Background Comorbid anxiety is generally associated with poorer response to
antidepressant treatment. This post hoc analysis explored the efficacy of esketamine plus an …

Abstract Background Treatment-resistant Depression (TRD) represents a widespread
disorder with significant direct and indirect healthcare costs. esketamine, the S-enantiomer …

Background The efficacy of esketamine in treatment-resistant depression (TRD) has been
confirmed. However, its administration is expensive and restrictive, with limited knowledge …

This narrative review aims to provide an overview of the current literature on the
pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of …

Background This study evaluated efficacy and safety of intravenous subanesthetic doses of
esketamine using an administration time of 10 minutes in patients with treatment-resistant …

Purpose Bipolar disorder is a chronic and recurrent condition often associated with
treatment resistance and suicidality. There is an unmet need for effective treatment in this …

ABSTRACT Introduction: Treatment Resistant Depression (TRD) is a common and
burdensome condition with poor outcomes and few treatment options. Esketamine is the S …

Background There is an urgent need to develop additional treatment strategies for patients
with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of …

Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-
resistant depression (TRD), showing both rapid antidepressant action and good efficacy and …